Drug intelligence / Profile preview

Baricitinib + Eltrombopag + Rituximab

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

The provided search results do not contain specific information about a three-drug combination therapy of baricitinib, eltrombopag, and rituximab. Information available describes the combination of eltrombopag and rituximab for treating refractory immune thrombocytopenia (ITP), and a separate mention of baricitinib being studied for steroid-resistant/relapse ITP.

Targets

TPOR (Thrombopoietin receptor)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on Baricitinib + Eltrombopag + Rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baricitinib + Eltrombopag + Rituximab.

Explore the full profile